|
Osteoarthritis Initiative Steering Group Agenda The Osteoarthritis Initiative-A Public-Private |
|
Monday, February 28, 2000 |
|
| 8:00 a.m. | |
| Welcome and Introductions | Stephen Katz, M.D., Ph.D. Director National Institute of Arthritis and Musculoskeletal and Skin Diseases Richard Hodes, M.D. Director; National Institute on Aging |
| 8:15 a.m. | |
| Presentation of Overall Focus and Structural Guidelines of the Osteoarthritis Initiative and Charge for Meeting | Stephen Katz, M.D., Ph.D. Director National Institute of Arthritis and Musculoskeletal and Skin Diseases Joan McGowan, Ph.D. Chief, Musculoskeletal Disease Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| 9:00 a.m. | |
| BIOCHEMICAL MARKERS Moderator Presentation of Biomarkers "White Paper" |
James Witter, M.D., Ph.D. Medical Officer Food and Drug Administration A. Robin Poole, Ph.D., D.Sc. Professor, Department of Surgery Director, Joint Disease Laboratory McGill University |
| 9:45 a.m. | |
| Perspectives on Biomarker Development and Use | David Eyre, Ph.D. Burgess Professor of Orthopaedic Research University of Washington Dick Heinegard, M.D., Ph.D. Professor, Department of Cell and Molecular Biology; University of Lund |
| 10:25 a.m. | |
| Coffee Break | Lobby |
| 10:45 a.m. | |
| Presentation of "straw" proposals Biomarkers Key Question: Are there biochemical markers that would allow assessment of response to disease-modifying therapies? |
Thasia Woodworth, M.D. Senior Associate Director Pfizer Central Research |
| 11:45 a.m. | |
| IMAGING Moderator Perspectives and Considerations on Imaging Techniques |
Randall Stevens, M.D. Director, Clinical Science Hoffman-LaRoche Laurance Hall, Ph.D. Herchel Smith Laboratory for Medicinal Chemistry Cambridge University Chris Buckland-Wright, Ph.D., D.Sc. Professor, Department of Applied Clinical Anatomy School of Biomedical Sciences; King's College London |
| 12:45 p.m. | |
| Lunch | Lister Hill Cafeteria |
| 1:30 p.m | |
| Presentation of "straw" proposals Imaging Techniques Key Question: Are structural features of the joint (hip or knee) and associated tissue changes (joint space narrowing and osteophytes) reliable markers of disease or disease progression? | Charles Peterfy, M.D., Ph.D. Chief Scientific Officer Executive Vice President Synarc, Inc. |
| 2:15 p.m. | |
| BIOSTATISTICS Moderator Presentation of Biostatistics "White Paper" |
Yetunde Taiwo, Ph.D. Section Head, Late Stage Arthritis Research Procter & Gamle Pharmaceuticals Ronald Helms, Ph.D. Vice President, Statistics; Rho, Inc. |
| 3:00 p.m. | |
| EPIDEMIOLOGY Moderator Presentation of Epidemiology "White Paper" |
Kenneth Brandt, M.D. Professor of Medicine Head, Rheumatology Division Director, Multipurpose Arthritis Disease Center Indiana University School of Medicine Marc Hochberg, M.D., M.P.H. Professor of Medicine and Epidemiology and Preventive Medicine; University of Maryland at Baltimore School of Medicine |
| 3:45 p.m. | |
| Perspectives on the Status of Current Cohort Studie | David Felson, M.D. Boston University Arthritis Center; Boston, MA Michael Nevitt, Ph.D., M.P.H. Department of Epidemiology and Biostatistics University of California, San Francisco |
| 4:15 p.m. | |
| Coffee Break | Lobby |
| 4:30 p.m. | |
| Presentation of "straw" proposals Epidemiology/Cohort Selection Key Question: Will the initiative be a single study or a composite of several studies to address needed areas of biomarker research in osteoarthritis? |
Leena Sharma, M.D. Assistant Professor of Medicine Division of Rheumatology Northwestern University |
| 5:15 p.m. | |
| ADMINISTRATION Moderator Presentation of "straw" proposals Initial Presentation of Administrative Model/Structure |
Gregory Downing, D.O., Ph.D. Health Science Policy Advisor Office of Science Policy, Office of the Director National Institutes of Health Stephen Stimpson, Ph.D. Exploratory Discovery Head Musculoskeletal Diseases Glaxo Wellcome Inc. |
| 6:15 p.m. | |
| Adjourn for Reception | |
|
DoubleTree Hotel Rockville |
|
| 6:30 p.m | |
| Reception | Plaza I Room |
| 8:00 p.m. | |
| Open Forums Feedback and Discussion: Session 1 - Biomarkers Session 2 - Imaging Session 3 - Epidemiology |
Randolph Room Regency Room Plaza II Room |
| 10:00 p.m. | |
| Adjourn until Tuesday morning | |
| Tuesday, February 29, 2000 | |
| Lister Hill Auditorium | |
| 8:00 a.m. | |
| CLINICAL END POINTS Moderator Perspectives on Clinical End Points for Osteoarthritis: Two Presentations With Discussion |
Virginia Kraus, M.D. Assistant Professor; Division of Rheumatology; Department of Medicine Duke University Deborah Freund, Ph.D. Vice Chancellor and Provost Syracuse University Representing the Arthritis Foundation Nicholas Bellamy, M.D., M.Sc. Director, Centre of National Research on Disability and Rehabilitation Medicine Faculty of Health Sciences The University of Queensland |
| 9:30 a.m. | |
| Summary of Biomarkers Session and Consensus | Thasia Woodworth, M.D. Senior Associate Director Pfizer Central Research James Witter, M.D., Ph.D. Medical Officer Food and Drug Administration |
| 10:15 a.m. | |
| Coffee Break | Lobby |
| 10:30 a.m. | |
| Summary of Imaging Session and Consensus | Charles Peterfy, M.D. Chief Scientific Officer Executive Vice President Synarc, Inc. Randall Stevens, M.D. Director, Clinical Science Hoffman-LaRoche |
| 11:15 a.m. | |
| Summary of Epidemiology Session and Consensus | Stefan Lohmander, M.D., Ph.D. Professor, Department of Orthopedics University Hospital University of Lund Kenneth Brandt, M.D. Professor of Medicine Head, Rheumatology Division Director, Multipurpose Arthritis Disease Center Indiana University School of Medicine |
| 12:00 p.m. | |
| Lunch | Lister Hill Cafeteria |
| 1:00 p.m. | |
| Summary of Administrative Session and Consensus | Stephen Stimpson, Ph.D. Exploratory Discovery Head Musculoskeletal Diseases Glaxo Wellcome Inc. Gregory Downing, D.O., Ph.D. Health Science Policy Advisor Office of Science Policy, Office of the Director; National Institutes of Health |
| 1:45 p.m. | |
| Next Steps | Stephen Katz, M.D., Ph.D. Director National Institute of Arthritis and Musculoskeletal and Skin Diseases Richard Hodes, M.D. Director National Institute on Aging |
| 2:05 p.m. | |
| Overall Initiative Proposal Moderator Presentation of "straw" proposals for InitiativeStatement, Clarification of Research Questions for Osteoarthritis Initiative |
Gayle Lester, Ph.D. Project Coordinator; Osteoarthritis Initiative National Institute of Arthritis and Musculoskeletal and Skin Disease Stefan Lohmander, M.D., Ph.D. Professor, Department of Orthopedics University Hospital University of Lund |
| 2:45 p.m. | |
| Coffee Break | Lobby |
| 3:00 p.m. | |
| Discussion and Consensus on Proposals for Osteoarthritis Initiative | Gayle Lester, Ph.D. Project Coordinator Osteoarthritis Initiative National Institute of Arthritis and Musculoskeletal and Skin Disease Stefan Lohmander, M.D., Ph.D. Professor, Department of Orthopedics University Hospital University of Lund |
| 4:00 p.m. | |
| Adjournment | |